Abstract

Current approaches to treating multiple sclerosis aim at controlling disease activity. Despite the variety of agents that have proven their effectiveness and were introduced in practice in the last decade, the use of the interferon β group remains relevant. The article presents clinical cases of long-term use of interferons β in treating multiple sclerosis.

Full Text

Published Version

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.